# US 2012/0252819 A1 · Solid dispersion formulations and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252819 A1
- Document ID: US20120252819A1
- Status: Published application
- Kind: A1
- Application number: 13/494,545
- Filed: 2012-06-12
- Published: 2012-10-04
- Earliest claimed: 2011-03-08
- Assignees: Zalicus Pharmaceuticals Ltd.
- Inventors: Mahesh V. Padval; Jeff T. Gautschi; Daniel T. Smithey; Marshall D. Crew; Abizer Harianawala
- Web page: https://patentgrep.com/patent/US20120252819A1

## CPC

- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to formulations and methods for increasing the bioavailability of 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one, 1-(3,3-diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more pharmaceutically acceptable matrix polymers to form a solid dispersion, e.g., a spray dried dispersion or a hot melt extrusion.

## Claims

### Claim 1

A pharmaceutical composition in unit dosage form for oral administration comprising a solid dispersion of from about 20 mg to about 250 mg of substantially amorphous compound 1 in a matrix polymer, wherein the percentage loading of said compound 1 in said solid dispersion is from about 10% to about 80% (w/w).

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the percentage loading of said compound 1 in said solid dispersion is from about 10% to about 50% (w/w).

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein said unit dosage form comprises from about 70 mg to about 250 mg of compound 1.

### Claim 4 (depends on 1)

A method to treat pain in a subject in need thereof, said method comprising administering to said subject an effective amount of the pharmaceutical composition of claim 1.
